Latest News

Q2 2022 Watch reviewing HCV treatment access across ADAPs, Medicaid, Veterans benefits, and assistance programs.

Q1 2022 assessment of HCV treatment access in ADAPs and Medicaid with DAA coverage and harm reduction data.

CANN announces 2022 organizational changes including rebranding and launching the 340B Action Center.

Q4 2021 Watch covering HCV drug formulary updates, ADAP and Medicaid changes, and pandemic impact on care.

31,000 Veterans with HIV face unique barriers including comorbidities and HCV rates 3x the general population.

Nobel laureate's HCV vaccine development targeting 2029 offers hope alongside access equity challenges.

Q3 2021 quarterly review of HCV drug access across ADAPs and Medicaid with harm reduction program updates.

CANN roundtable discusses pandemic's impacts on HIV, HCV, STI, and SUD programs and funding weaknesses.

Study of 109,283 patients links HIV status and viral hepatitis coinfection to significantly increased liver cancer rates.

Quarterly update on HCV treatment coverage across ADAPs, Medicaid, Veterans programs, and patient assistance options.

Assesses pandemic's ongoing impact on HIV, HCV, and SUD surveillance and care with vaccine rollout.

Multi-state Hepatitis A and B outbreaks linked to homelessness highlight housing as public health priority.

HHS releases integrated Viral Hepatitis National Strategic Plan calling for a syndemic approach with HIV and STI.

Quarterly Watch covering HCV treatment access across ADAPs and Medicaid, harm reduction programs, and COVID-19 impact on care.

Evaluates pandemic's impacts on HIV, HCV, and SUD services including testing disruptions and telehealth expansion.

CANN outlines advocacy priorities for the Biden era, from 340B reform and drug pricing to HIV criminalization and health equity.